Understanding Biosimilars
Biosimilars are biologic medications that are developed to be highly similar to an already approved biologic drug, known as the reference product. While biosimilars are developed to be interchangeable with the reference product, there are minor differences in formulations or manufacturing processes compared to the original biologic. For a biosimilar to gain regulatory approval, extensive testing must demonstrate its similarity in purity, potency, and safety to the reference product.
The Development Process
Developing a biosimilars Insulin is more complex than creating a traditional small-molecule generic drug due to the larger, more complex structure of biologics. Biosimilars undergo rigorous testing and clinical trials to prove they are highly similar in clinical effect to the reference product. Developers must characterize the structure of the reference product and biosimilar to ensure similarity. Non-clinical studies assess toxicity, and clinical pharmacology trials demonstrate comparable pharmacokinetic and pharmacodynamic profiles to the reference product. Pivotal clinical trials then show equivalent efficacy, safety, and immunogenicity.
The Global Insulin Market
The global insulin market was valued at nearly $29 billion in 2020 and is projected to grow at a 5% compound annual growth rate through 2027. Approximately 8.5% of the global population has diabetes, with most relying on insulin therapy to manage their condition. However, the high list prices of branded insulins place a significant burden on patients and healthcare systems worldwide. The development of insulin biosimilars presents an opportunity to improve access and affordability for the millions who depend on insulin daily.
Earlier Biosimilar Insulins
The first insulin biosimilar, Insulin Glargine Basaglar, was approved by the EMA and FDA in 2015/16. Other biosimilar insulins have since gained approval including Lusduna (insulin glulisine) and Semglee (insulin glargine). Clinical trials found these insulins were as safe and effective as their reference products with comparable glucose-lowering effects. Real-world studies also show insulin biosimilars offer savings of 20-30% off the list price of originator biologics. With ongoing patent expirations of insulin formulations, additional biosimilars are poised to enter markets and drive further competition.
Barriers to Biosimilar Uptake
While biosimilar insulins present a more affordable treatment option, several barriers have slowed their uptake and market penetration globally. One challenge is altering clinical practice and switching patients who are stable on their current insulin regimens. Healthcare providers may also lack comprehensive education on the stringent development and approval processes for biosimilars. At a regulatory level, naming conventions that differentiate biosimilars from originators can reduce automatic substitution and uptake in pharmacy settings. However, as clinical experience and real-world evidence accumulates, biosimilars are gaining greater acceptance among physicians and patients.
Future Outlook and Growth Opportunities
Looking ahead, several insulin formulations poised for biosimilar competition in the coming years offers optimism for improving access and lowering treatment costs. Originator biologics Humalog and NovoLog comprised nearly 60% of the global insulin market in 2020 and both are biosimilar-eligible in major regions. While the U.S. market has lagged Europe and other regions in biosimilar adoption to date, upcoming patent expirations will drive greater penetration. Emerging growth opportunities also exist in developing countries where insulin access remains limited due to high prices. As the cost differential and real-world utilization data grows more compelling, biosimilars have significant potential to transform global diabetes treatment by making lifesaving insulin therapy affordable for all.
Comments
0 comment